Terms: = Ovarian cancer AND PAX8, ENSG00000125618, 7849 AND Prognosis
32 results:
1. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract] [Full Text] [Related]
2. Significance analysis of pax8 expression in endometrial carcinoma.
Hu S; Gan H; Yang F
Medicine (Baltimore); 2022 Oct; 101(42):e31159. PubMed ID: 36281161
[TBL] [Abstract] [Full Text] [Related]
3. Membranous and nuclear staining of CLDN18 in HPV-independent and HPV-associated endocervical adenocarcinomas.
Du X; Hu Y; Ji X; Sui L; Zheng Q; Song K; Lv T; Chen Y; Zhao H; Dai S; Zhao P; Yao Q
Cancer Med; 2023 Jan; 12(2):1441-1450. PubMed ID: 35861118
[TBL] [Abstract] [Full Text] [Related]
4. Construction and Characterization of Cadherin 6 (CDH6)-Targeting Chimeric Antigen Receptor (CAR) Modified T Cells.
Pang L; Ren F; Xu X; Fu L; Wang T; Guo Z
J Environ Pathol Toxicol Oncol; 2022; 41(1):55-71. PubMed ID: 35378004
[TBL] [Abstract] [Full Text] [Related]
5. pax8 and MECOM are interaction partners driving ovarian cancer.
Bleu M; Mermet-Meillon F; Apfel V; Barys L; Holzer L; Bachmann Salvy M; Lopes R; Amorim Monteiro Barbosa I; Delmas C; Hinniger A; Chau S; Kaufmann M; Haenni S; Berneiser K; Wahle M; Moravec I; Vissières A; Poetsch T; Ahrné E; Carte N; Voshol J; Bechter E; Hamon J; Meyerhofer M; Erdmann D; Fischer M; Stachyra T; Freuler F; Gutmann S; Fernández C; Schmelzle T; Naumann U; Roma G; Lawrenson K; Nieto-Oberhuber C; Cobos-Correa A; Ferretti S; Schübeler D; Galli GG
Nat Commun; 2021 Apr; 12(1):2442. PubMed ID: 33903593
[TBL] [Abstract] [Full Text] [Related]
6. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract] [Full Text] [Related]
7. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract] [Full Text] [Related]
8. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
9. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma.
De Thaye E; Van de Vijver K; Van der Meulen J; Taminau J; Wagemans G; Denys H; Van Dorpe J; Berx G; Ceelen W; Van Bocxlaer J; De Wever O
Sci Rep; 2020 Apr; 10(1):6688. PubMed ID: 32317693
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract] [Full Text] [Related]
11. [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].
Höhn AK; Brambs CE; Opitz S; Erber R; Hartmann A; Horn LC
Pathologe; 2019 Nov; 40(6):609-618. PubMed ID: 31578630
[TBL] [Abstract] [Full Text] [Related]
12. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.
Bi R; Bai Q; Zhu X; Tu X; Cai X; Jiang W; Xu X; Tang S; Ge H; Chang B; Cheng Y; Gan H; Zhou X; Yang W
Diagn Pathol; 2019 Aug; 14(1):96. PubMed ID: 31455365
[TBL] [Abstract] [Full Text] [Related]
13. Breast metastasis two years after pelvic surgery and adjuvant chemotherapy for serous ovarian cancer.
Della Corte L; Giampaolino P; Fabozzi A; Cieri M; Zizolfi B; Morra I; Bifulco G
Gynecol Endocrinol; 2019 Mar; 35(3):211-213. PubMed ID: 30449229
[TBL] [Abstract] [Full Text] [Related]
14. Tubo-ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.
Magrill J; Karnezis AN; Tessier-Cloutier B; Talhouk A; Kommoss S; Cochrane D; Chow C; Cheng A; Soslow R; Hauptmann S; du Bois A; Pfisterer J; Gilks CB; Huntsman DG; Kommoss F
Int J Gynecol Pathol; 2019 Nov; 38(6):552-561. PubMed ID: 30059451
[TBL] [Abstract] [Full Text] [Related]
15. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract] [Full Text] [Related]
16. The Challenge of Evaluating Adnexal Masses in Patients With Breast cancer.
Reinert T; Nogueira-Rodrigues A; Kestelman FP; Ashton-Prolla P; Graudenz MS; Bines J
Clin Breast Cancer; 2018 Aug; 18(4):e587-e594. PubMed ID: 29680194
[TBL] [Abstract] [Full Text] [Related]
17. Dedifferentiated carcinoma of the ovary. A case report.
Němejcová K; Rosmusová J; Bártů M; Matěj R; Dundr P
Cesk Patol; 2018; 54(1):33-36. PubMed ID: 29631410
[TBL] [Abstract] [Full Text] [Related]
18. [Significance and expression of pax8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
19. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
[TBL] [Abstract] [Full Text] [Related]
20. Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium.
Bajwa P; Nagendra PB; Nielsen S; Sahoo SS; Bielanowicz A; Lombard JM; Wilkinson JE; Miller RA; Tanwar PS
Oncotarget; 2016 Apr; 7(15):19214-27. PubMed ID: 27036037
[TBL] [Abstract] [Full Text] [Related]
[Next]
